Human FCRL5 Antibody

Catalog #: MAB20872 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB20872-100
MAB20872-SP

Detection of FCRL5 in Human Lymphocytes by Flow Cytometry.

1 Image

All FCRL5 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human FCRL5 Antibody Summary

Species Reactivity

Human

Specificity

Detects human FCRL5 in direct ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 1010552

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line, NS0-derived human FCRL5 protein
Gln16-Arg844
Accession # Q96RD9

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Flow Cytometry

0.25 µg/10⁶ cells

Human Peripheral Blood Lymphocytes

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry

View Larger

Detection of FCRL5 in Human Lymphocytes by Flow Cytometry. Human blood-derived lymphocytes were stained with (A) Mouse Anti-Human FCRL5 Monoclonal Antibody (Catalog # MAB20872) or (B) Mouse IgG1 isotype control antibody (MAB002), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (F0101B) and PE-conjugated Mouse Anti-Human CD19 Monoclonal Antibody (FAB4867P).

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FCRL5

Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836 amino acid (aa) extracellular domain (ECD) with nine Ig-like domains, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs) (1, 3). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains (3, 4). FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood (3, 5‑7). Its ligation inhibits signaling through the B cell antigen receptor (8). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (9). The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities (3). FCRL5 is up‑regulated on tumor cells in some types of B cell malignancies (6, 10‑12). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (11, 13).

References

Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
Hatzivassiliou, G. et al. (2001) Immunity 14:277.
SwissProt # Q96RD9.
Miller, I. et al. (2002) Blood 99:2662.
Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
Mohan, J. et al. (2006) Blood 107:4433.
Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
Ise, T. et al. (2007) Leukemia 21:169.
Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.

Long Name

Fc Receptor-like 5

Entrez Gene IDs

83416 (Human); 329693 (Mouse)

Alternate Names

BXMAS1; BXMAS1MGC119592; CD307; CD307e antigen; CD307e; DKFZp667E2019; DKFZp667F216; Fc receptor homolog 5; Fc receptor-like 5; Fc receptor-like protein 5; FcRH5; FCRH5MGC119593; FCRL5; FcR-like protein 5; FLJ00333; FLJ00397; IFGP5; Immune receptor translocation-associated protein 2; immunoglobulin superfamily receptor translocation associated 2 (IRTA2); IRTA2; IRTA2MGC119590; PRO820